Recognition in a Difficult Quarter

In Q1 2025, Business Weekly published its latest Killer50 showcase – a long-standing benchmark for innovation in UK life sciences. Isogenica, a specialist in synthetic VHH antibody discovery, was recognised in the Ones2Watch category for its scientific credibility and commercial momentum. 

This recognition comes amid a difficult quarter for the industry globally. Nevertheless, five life science ventures in the Killer50 list raised nearly $500 million in funding. That group included companies like surgical robotics provider CMR Surgical (over $200 million raised) and antibody therapeutics startup Maxion Therapeutics ($72 million Series A) [1].

Being listed alongside such ventures is a powerful endorsement of Isogenica’s position in the UK’s innovation ecosystem — a trusted partner accelerating antibody discovery for global biopharma. 

In this blog, we explore why this accolade matters to Isogenica – from showcasing its peer credibility and investor appeal to opening doors for new partnerships.

In the photo, Trevor Phillips and Lurdes Duarte, from Isogenica, at the Killer50 Technology networking event on May 1st, 2025. Photo credit: Phil Mynott 

In a Crowded Biotech Market, Trust is the Differentiator

In today’s biotech arena, even the most innovative platforms face a credibility challenge. Especially in antibody discovery, where speed and specificity are essential, trust is earned through evidence – not claims. Drug discovery is crowded with new technologies, and potential pharma partners and investors must decide which collaborators truly add value. To stand out as a discovery platform provider like Isogenica requires not only promising data but consistent results, validated platforms, and industry recognition. 

Located in the heart of the Cambridge biotech cluster – one of the world’s leading innovation ecosystems – Isogenica benefits from a rich network of collaborators, scientific talent, and early-stage capital.

The difficulty is that early-stage companies often have limited track records, making external validation crucial. Reputation can be a make-or-break factor: without it, breakthrough science may be overlooked or struggle to secure funding and partnerships.

In an environment where seven Killer50 companies collectively drew almost $500 million in a challenging quarter, credibility is crucial. Being part of such high-performing peers directly closes the trust deficit, stating to potential partners that Isogenica’s expertise and track record place it at the forefront of the region’s biotech innovators. Third-party endorsement helps partners navigate a crowded field, signalling that Isogenica delivers real-world results in antibody discovery – with platform performance trusted by global biopharma. 

Why Isogenica’s Platform Is Gaining Global Traction 

Built for scientists, Isogenica’s synthetic VHH discovery platforms help pharma partners move from idea to IND-ready leads faster – with greater specificity and fewer development dead ends. Unlike service-only CROs, Isogenica offers true discovery engines – proprietary synthetic VHH libraries and display platforms developed in-house, giving partners a speed and specificity edge.

Isogenica overcomes the credibility hurdle with tangible results, established track record, and a peer-level, science-first approach to collaboration.  Its strategy for earning market trust can be distilled into a few core strengths:

First, innovative Antibody Platform: Isogenica has developed proprietary synthetic antibody discovery technologies – including fully synthetic, pre-humanised VHH libraries and its CIS Display™ system  – that enable broad searches for drug candidates. This platform interrogates up to 1000× more antibody sequences than standard screening methods, increasing the chances of finding high-affinity, developable binders.

Second, proven partnerships and pipeline: Isogenica has secured partnerships with top-tier biopharma companies like AstraZeneca and Takeda, who have published on their successes. The outcomes of such alliances are telling – Isogenica’s partnered programs now include multiple candidates in clinical trials — a pipeline that reflects both platform scalability and partner confidence. Each success story with a partner further cements Isogenica’s reputation as an enabler of therapeutic innovation.

Last but not least, a collaborative, evidence-led approach: Isogenica stands out for its peer-to-peer working style, aligning closely with partner goals. Recent feedback speaks for itself: 100% of VHH discovery clients rated Isogenica 8 – 10 (out of 10) in likelihood to recommend. By acting as a true collaborator—not just a vendor—Isogenica builds lasting, trust-based relationships with biotech and pharma teams.

Isogenica has earned a place in the Killer50 Ones2Watch category by doing what matters: delivering results.

Curious about our partnerships? Explore our clients and case studies. 

Sources

[1] Cambridge Network (2025) Killer50 companies raise megabucks in Q1 2025